Transaction DateRecipientSharesTypePriceValue
1st February 2021Richard Peters60,943Grant/award etc.$0.00
1st February 2021Richard A. Heyman1,959Grant/award etc.$0.00
1st February 2021Cecil B Pickett1,959Grant/award etc.$0.00
1st February 2021N Anthony Coles1,118Grant/award etc.$0.00
1st February 2021Jeffery W. Kelly1,959Grant/award etc.$0.00
1st February 2021Paulash Mohsen4,665Grant/award etc.$0.00
13th November 2020N Anthony Coles11Exercise of derivative$345.47$3,800.17
17th August 2020N Anthony Coles2,453Open or private sale$156.77$384,559.26
29th July 2020N Anthony Coles1,157Grant/award etc.$0.00
10th June 2020Enterprise Associates 12, Limited Partnership New1,482,809Other acquisition or disposition$0.00
Proteostasis Therapeutics
Proteostasis Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases.

Ticker: PTI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1445283
Employees: 44
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags